Dengue Vaccine
Pathophysiology And Challenges
- Dengue virus comprises four distinct serotypes.
- Natural infection confers lifelong homotypic immunity.
- Heterotypic immunity remains transient.
- Sub-neutralizing antibodies form complexes with dengue virus.
- Complexes paradoxically facilitate viral cell entry in host monocytes and macrophages.
- Phenomenon termed Antibody-Dependent Enhancement increases severe disease risk during secondary heterotypic infection.
- Vaccine must generate balanced neutralizing immunity against all four serotypes to prevent vaccine-related Antibody-Dependent Enhancement in seronegative individuals.
Licensed Vaccines
Dengvaxia
- Recombinant live-attenuated tetravalent vaccine.
- Utilizes yellow fever 17D virus backbone.
- Administered via three subcutaneous doses at 0, 6, and 12 months.
- Approved for ages 9-45 years.
- Pre-vaccination screening mandatory.
- Indicated strictly for individuals with laboratory-confirmed prior dengue infection.
- Seronegative recipients face heightened risk of severe dengue hospitalization due to Antibody-Dependent Enhancement.
- Efficacy remains higher against serotypes 3 and 4.
Qdenga
- Recombinant live-attenuated tetravalent vaccine.
- Utilizes dengue serotype 2 backbone.
- Administered via two subcutaneous doses 3 months apart.
- Indicated for adults, adolescents, and children older than 4 years.
- World Health Organization recommends administration for ages 6-16 in high-transmission settings.
- Sero-independent; pre-vaccination screening unnecessary.
- Efficacy reaches 80.9% overall and 95.4% against hospitalization at 12 months.
- Overall efficacy declines to 61.2% over 4.5 years.
Emerging Vaccines
Butantan-DV
- Live-attenuated chimeric tetravalent vaccine.
- Utilizes attenuated dengue serotype 4 backbone.
- Administered as single subcutaneous dose.
- Approved in Brazil for ages 12-59 years.
- Sero-independent administration.
- Demonstrates 80.5% effectiveness against severe dengue over 5 years.
- Achieves 100% protection against dengue-related hospitalizations.
V181
- Investigational quadrivalent vaccine currently in Phase 3 trials.
- Utilizes purified inactivated virus technology.
- Eliminates vaccine-induced viremia risk.
- Potentially safe for immunocompromised populations and pregnant women.
Comparative Analysis
| Feature | Dengvaxia | Qdenga | Butantan-DV |
|---|---|---|---|
| Platform Backbone | Yellow fever 17D | Dengue serotype 2 | Dengue serotype 4 |
| Dosing Schedule | 3 doses (0, 6, 12 months) | 2 doses (0, 3 months) | Single dose |
| Target Age | 9-45 years | >4 years | 12-59 years |
| Serostatus Requirement | Strictly seropositive | Sero-independent | Sero-independent |
| Administration Route | Subcutaneous | Subcutaneous | Subcutaneous |
Contraindications And Precautions
- Live-attenuated dengue vaccines contraindicated in immunocompromised individuals.
- Contraindicated in symptomatic human immunodeficiency virus infection.
- Contraindicated during pregnancy and lactation.
- Contraindicated in individuals with severe hypersensitivity to previous doses.